Otsuka

News

Vertex chief executive Reshma Kewalramani

Vertex preps FDA filing for IgAN drug after phase 3 readout

Vertex's bid to expand beyond cystic fibrosis has taken a big step forward with phase 3 data for povetacicept in severe kidney disorder IgAN.

News

ADHD in wooden letters surrounded by white pills

Otsuka preps for July decision on centanafadine for ADHD

The FDA has started a priority review of Otsuka's triple-acting drug for ADHD, setting up a decision on the first-in-class drug in July.

News

CMS's Medicare price negotiations start round three

The US federal government has named the next 15 big-selling medicines that will be subject to Medicare pricing negotiations.

News

Man looking through red lenses of binoculars

11 high-impact drugs to look out for in 2026

Medicines for obesity, diabetes, rare diseases, cancer, and women's health feature among Clarivate's annual round-up of 11 Drugs to Watch this year.

News

EU approves Otsuka's long-acting HAE drug Dawnzera

An EMA nod for Otsuka's Dawnzera offers EU patients with HAE a drug that can be self-administered by patients with up to eight weeks between doses.

News

Otsuka joins IgAN market with Voyxact approval in US

Otsuka has claimed FDA approval for its IgAN therapy Voyxact, joining an increasingly crowded market and beating rival Vera Therapeutics to the punch.

Vertex preps FDA filing for IgAN drug after phase 3 readout

Otsuka preps for July decision on centanafadine for ADHD

CMS's Medicare price negotiations start round three

11 high-impact drugs to look out for in 2026

EU approves Otsuka's long-acting HAE drug Dawnzera

Otsuka joins IgAN market with Voyxact approval in US

After setback, Rhythm gets good news on Imcivree from FDA

Using AI-driven synthetic personas to take your insights fur...

Otsuka

Editor's Picks